[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fJUYZaKzGYZZFKFrQXJLG1e4qZCxWhV5b2fLrad3TXyU":8,"$fr1gFpSh56BgZoyfKSxjz2BafUTyeSBtuY-nUmuXG18U":90,"$fxo7O-DluTqmyInrZRDVU5yHRHBnk-JBOSRmSHxZ15Nk":91,"$fK_BLSvAxa7F4uD4efC0UGw01HBAsAIvZaWIcagCYxDg":95},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":89},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"roleType":17,"adept":18,"hospital":19,"department":20,"postsTitle":21,"materialTotal":17,"videoTotal":22,"isConcern":7,"title":23,"coverVertical":24,"coverAcross":25,"directionMarker":26,"description":27,"vid":28,"time":29,"mediaType":30,"views":31,"likes":17,"isThumbsUp":7,"isCollection":7,"collections":17,"createTime":32,"seoTitle":23,"seoKeywords":33,"seoDescription":34,"shelvesTime":35,"menus":36,"menuId":77,"type":26,"quality":87,"commentCount":17,"isComment":30,"deviceType":40,"url":88},28726,890682,[],"https://ystcdn.venuertc.com/venue/app/34076/2026-06-07/d1d67294-cf86-4d15-969f-be2ca1320878.png","屠小龙",0," 肺癌、胃癌、肠癌、乳腺癌等恶性肿瘤的诊治 恶性肿瘤术后及放化疗后的中医综合调理","宁波市中医院","肿瘤科","副主任医师",16,"乳腺癌的靶向治疗选择策略怎么一步步落实","https://cdn.yishi-tong.com/console/3/utgy7ORRbdY99ruMcZ1lylpjkctfhEzH.png","https://cdn.yishi-tong.com/console/3/QvHkESFt4ZZyHF3wUtygaB29DXjPLd-q.png",2,"\u003Cdiv>\u003Ch3>乳腺癌的靶向治疗选择策略怎么一步步落实！\u003C/h3>\u003Ch3>乳腺癌靶向治疗往往被忽略的细节:\u003C/h3>\u003Ch3>🌸\u003C/h3>\u003Cp>乳腺癌的靶向治疗选择，很多朋友以为只要听医生安排就行，其实每一步都和身体情况息息相关。今天咱们专门聊聊乳腺癌的靶向治疗选择策略，带大家好好梳理一下从发现到治疗的关键环节。\u003C/p>\u003Cp>乳腺癌都需要用科学的靶向策略对症下药。咱们乳腺癌的治疗一步都不能慢慢来，要抓住合适时机，选对合适的药。\u003C/p>\u003Ch3>影响靶向治疗选择的三个关键因素？\u003C/h3>\u003Ch3>🔬\u003C/h3>\u003Cp>第一，明确乳腺癌的分子分型。乳腺癌不是一个模子刻出来的，医院会做一系列免疫组化检测，比如检测HER2、雌激素受体（ER）、孕激素受体（PR）等，就是判断肿瘤属于哪一类。只有搞清楚分型，才知道身体对哪种靶向药敏感。\u003C/p>\u003Cp>第二，是否存在HER2阳性。HER2阳性的乳腺癌患者，临床常用针对HER2的靶向药物，比如曲妥珠单抗。有没有这个阳性结果，就像是能不能用钥匙打开门的条件，相关药物只针对这一类肿瘤发挥作用。\u003C/p>\u003Cp>第三，治疗周期与身体状况。有些靶向药物需要和化疗、内分泌治疗一起用，有些则单独用。医生要评估肝肾功能、心脏健康和自身免疫情况，确保治疗方案既有效，又不会留下新问题。\u003C/p>\u003Ch3>实际操作中应该先做哪些准备:\u003C/h3>\u003Ch3>📝\u003C/h3>\u003Ch3>乳腺癌的靶向治疗选择策略里建议这样做：\u003C/h3>\u003Cp>建议怎么做：充分和医生交流自己的病理类型、检验报告和身体基础情况。详细问清楚HER2、ER、PR是不是阳性，确认自己适合哪一类靶向药。不少乳腺癌患者抗药性会慢慢发生变化，需要定期复查，及时调整方案。\u003C/p>\u003Cp>不建议怎么做：不要只听别人说哪种药好就盲目追求靶向治疗。乳腺癌的靶向药并不是每个人都适用，更不能替代化疗或手术。\u003C/p>\u003Ch3>乳腺癌靶向治疗选择需要持续关注自身变化！\u003C/h3>\u003Ch3>💡\u003C/h3>\u003Cp>总结一下，乳腺癌靶向治疗选择策略最关键是对症分型、科学配药、定期随访。乳腺癌并不是一成不变，治疗期间身体的反应每一步都值得关注。遇到乳腺癌的相关问题，理性就医，持之以恒非常重要。\u003C/p>\u003C/div>","v0247cg10004da1sb227dld4rip1dhqg",218,1,853,"2026-08-06 14:37:48","乳腺癌, 靶向治疗, HER2阳性, 分子分型, 治疗方案, 身体状况, 定期复查, 抗药性","本篇文章深入探讨乳腺癌靶向治疗的选择策略，强调分子分型、HER2阳性及身体状况对治疗的影响，助您科学决策，保障健康。","2026-08-25 17:18:55",[37,58,76],{"menuId":38,"menuName":39,"parentId":17,"orderNum":40,"path":41,"component":42,"isFrame":43,"isCache":44,"menuType":45,"visible":30,"status":17,"createDept":6,"remark":46,"createTime":47,"children":48,"columnImage":49,"columnLogo":50,"uncheckedLogo":51,"checkedLogo":52,"isHot":30,"isHome":17,"forceLogin":17,"color":53,"seoTitle":54,"seoKeywords":55,"seoDescription":55,"contentNum":6,"promotionalPoster":56,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":57,"routerPath":41,"componentInfo":42},"1997925012023775234","热门频道",4,"column","/column/tcm_index.html","1","0","T","","2025-12-08 15:03:37",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:10:18/ef345cdc-bb06-4db5-b74d-6ecfafabe83e.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:10:21/81815950-9711-4b40-8543-421bd7701d0f.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:10:32/99452289-a401-4ab2-ae91-2a1a1f7442d1.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:10:29/f52b1198-7225-4f72-89f3-605e6a14f530.png","#42a5f6","sadf","asdf","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:10:25/cf4f002d-c534-4c28-b405-a2e504dc5188.png","Column",{"menuId":59,"menuName":60,"parentId":38,"orderNum":61,"path":62,"component":63,"isFrame":43,"isCache":44,"menuType":45,"visible":30,"status":17,"createDept":6,"remark":46,"createTime":64,"children":65,"columnImage":66,"columnLogo":67,"uncheckedLogo":68,"checkedLogo":69,"isHot":17,"isHome":17,"forceLogin":17,"color":70,"seoTitle":71,"seoKeywords":72,"seoDescription":73,"contentNum":6,"promotionalPoster":74,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":75,"routerPath":62,"componentInfo":63},"1989172310225670145","公益项目",6,"public","/column/public_index.html","2025-11-14 11:23:30",[],"https://ystcdn.venuertc.com/venue/undefined/2025-12-18-14:41:13/1b7a5e2b-9e7d-4769-851f-1c55c481fa82.png","https://ystcdn.venuertc.com/venue/undefined/2025-12-18-14:41:18/b79a0a5e-411c-4282-8eaf-86fcc7e492bf.png","https://ystcdn.venuertc.com/venue/undefined/2025-12-24-16:17:17/6f411ecf-82d8-4fb5-9371-fa7faba2cb8f.png","https://ystcdn.venuertc.com/venue/undefined/2025-12-24-16:17:16/93f832c4-2264-4094-88fd-6fd80c8d9369.png","#80cbc4","健康科普工公益行——携手共建健康未来","健康,科普,公益行,健康知识,公众健康,社会健康,健康活动,健康意识","健康科普工公益行活动,传播健康知识,提高公众健康意识,共同促进社会健康发展,关注您和家人的健康！","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:12:46/1f2ac83a-c564-4aeb-ad97-5b5c4f09bfa5.png","Public",{"menuId":77,"menuName":78,"parentId":59,"orderNum":61,"path":79,"component":80,"isFrame":43,"isCache":44,"menuType":45,"visible":30,"status":17,"createDept":6,"remark":46,"createTime":81,"children":82,"columnImage":83,"columnLogo":6,"uncheckedLogo":6,"checkedLogo":6,"isHot":17,"isHome":17,"forceLogin":17,"color":6,"seoTitle":78,"seoKeywords":84,"seoDescription":85,"contentNum":6,"promotionalPoster":6,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":86,"routerPath":79,"componentInfo":80},"2047224557296840705","“健康中国-医路相伴健康同行”肿瘤领域科普传播计划","publicTFPAPP","/column/public_publicTFPAPP","2026-04-23 16:02:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-04-23-15:59:55/812f101e-9b62-472f-b155-2cb356602a89.png","肿瘤科普、癌症科普、肿瘤防治、科学抗癌、健康中国科普、医路相伴健康同行","响应 \"健康中国 2030\" 战略，\"健康中国 - 医路相伴健康同行\" 肿瘤领域科普传播计划，联合权威医学专家，提供肿瘤预防、筛查、治疗、康复全周期科学科普内容，普及抗癌知识，破除健康误区，助力全民肿瘤防治素养提升。","PublicTFPAPP","癌症肿瘤","https://vod.haohuanjiao.com/huanjiao/specialistVideo/890682/bc8d1d8b-33b4-4500-b92f-c79d2818461d.tmp?a=0&auth_key=1790351893-1739e1be945a40efb6d6398f6626af52-0-edb3225c4cad9c1bdcf6ab37c20b6839&br=754&bt=754&cd=0%7C0%7C0&ch=0&cr=0&cs=0&dr=0&ds=3&eid=v0247cg10004da1sb227dld4rip1dhqg&er=0&l=20260826135436BF923D39DA0ABCAFFF70&lr=&mime_type=video_mp4&net=0&pl=0&qs=13&rc=ams0bDdvOjV2ZDczNGY3M0ApdGdzdWdnNWU0ZzMzajo1eWduYW1vYWEvXy5hLS1kNC9zc2RlLmYxaTQvcF4xLS5gMS06Yw%3D%3D&vl=&vr=",true,{"code":9,"msg":88,"message":6,"data":6,"success":89},{"code":9,"msg":10,"message":6,"data":92,"success":89},{"pageNo":30,"pageSize":93,"result":94,"totalSize":17},10,[],{"code":9,"msg":10,"message":6,"data":96,"success":89},{"authors":97,"appraiseDimensionScoresVos":98},[],[]]